Given that previous studies have implicated TIMP1 in promoting tumor proliferative abilities and metastasis both in vitro and in vivo (B. Ma et al., 2022; Rao et al., 2022; Song et al., 2016), the findings position the TIMP1-centered signaling axis as a potential therapeutic target in CRC. Here, TIMP1 is linked to neoplasm.